FC
TVTX icon

FORA Capital’s Travere Therapeutics TVTX Stock Holding History

FORA Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,023
Closed -$358K – 604
2025
Q4 		$358K Buy
+8,023
New +$261K 0.04% 346
2020
Q4 		– Sell
-2,387
Closed -$44K – 1146
2020
Q3 		$44K Sell
2,387
-5,679
-70% -$110K 0.03% 457
2020
Q2 		$165K Buy
8,066
+4,520
+127% +$72K 0.06% 392
2020
Q1 		$52K Buy
+3,546
New +$53.4K 0.01% 764

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FORA Capital's TVTX Position: Q1 2026 in Review

FORA Capital sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 8,023 shares — an estimated $358K sold.

FORA Capital first reported a position in TVTX in Q1 2020 and held it in 4 quarters. The position peaked at $358K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • FORA Capital reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • FORA Capital sold 8,023 Travere Therapeutics shares in Q1 2026, an estimated $358K.
  • FORA Capital first reported a position in Travere Therapeutics in Q1 2020 and held it in 4 quarters.
  • FORA Capital's Travere Therapeutics position peaked at $358K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.